This article is written for research and educational purposes only. The compounds, peptides and molecules discussed have not been approved for human use by any regulatory authority. Nothing in this article constitutes medical advice, a treatment recommendation, or a dosage guideline. Helix supplies research-grade compounds exclusively for in vitro and preclinical research use.

 

What "GLP-5" Actually Refers To

The compound sold under the name [Glp5] Substance P (5-11) (CAS 56104-22-4) is a real, catalogued research peptide, but it has nothing to do with the glucagon-like peptide family that includes GLP-1 and GLP-2.

Here, "Glp" stands for pyroglutamyl (also written pGlu), a modified amino acid residue commonly found at the N-terminus of naturally occurring peptides. It's standard peptide-chemistry shorthand, used across countless unrelated compounds, and it happens to visually collide with the abbreviation for "glucagon-like peptide." The overlap is coincidental, not biological.

Strip away the naming confusion, and what you have is an octapeptide fragment of Substance P, corresponding to residues 5 through 11 of the full undecapeptide, with the sequence Glp-Gln-Phe-Phe-Gly-Leu-Met-NH₂. It belongs to the tachykinin family and acts through neurokinin (NK) receptors (the same receptor system covered in our recent piece on Substance P's role in tissue-regeneration research), not the GLP-1 receptor pathway that underlies incretin-based metabolic drugs.

What the Research Actually Shows

The foundational study on this fragment, published in the European Journal of Pharmacology in 1995, examined how Substance P (1-7) and Substance P (5-11) locally modulate dopamine release in the rat striatum. The findings describe a narrow, concentration-dependent effect on dopamine outflow in a specific brain region of the rat central nervous system, a far cry from systemic glucose regulation, appetite suppression, or the multi-organ metabolic effects associated with GLP-1 receptor agonists.

Subsequent characterizations note the fragment's relevance to dopaminergic signaling and its use as a pharmacological tool in neuropharmacology research, alongside separate exploratory work using radiolabeled Substance P (5-11) as a targeting ligand in glioma cell studies. None of this literature positions the molecule as a metabolic agent, an incretin mimetic, or a successor to any GLP-numbered hormone.

Why the Name Collision Happened

Peptide research catalogs are enormous, and naming conventions weren't built with SEO or public search behavior in mind. "Glp" as a residue abbreviation predates the fame of GLP-1 by decades; it simply describes a chemical modification, the way "Ac-" denotes an acetylated N-terminus. When a molecule bearing that modification happens to be numbered "5" in its own catalog system, the result reads, to anyone unfamiliar with peptide shorthand, like "GLP-5," the fifth entry in a hormone family that only actually goes up to GLP-2.

It's a useful reminder for anyone navigating RUO peptide catalogs: product names are chemical shorthand, not always a reliable guide to a compound's biological family or mechanism. Verifying the actual receptor target and published pharmacology, rather than reading the name at face value, is the difference between accurate research context and a false lead.

So What Is Actually Next After GLP-1?

If the question is which research compounds represent the genuine next step beyond single-receptor GLP-1 agonism, the honest answer lies in multi-receptor agonism. The research and clinical pipeline built on GLP-1's foundation has moved toward molecules that engage several metabolic hormone pathways at once:

• Dual GLP-1/GIP agonism: the mechanism behind tirzepatide, already in clinical use, which layers a second incretin pathway onto GLP-1 receptor activation.

• Triple GLP-1/GIP/glucagon agonism: exemplified by retatrutide, currently the most advanced triple-receptor candidate, combining incretin effects with glucagon receptor activity to increase energy expenditure alongside appetite regulation.

• GLP-1/amylin combinations: pairing GLP-1 receptor agonism with amylin-pathway activity to influence satiety through a distinct hormonal axis.

These are the molecules genuinely built on GLP-1's mechanistic legacy, each adding a receptor target with its own preclinical and clinical rationale. That's a very different proposition from a same-sounding name attached to an unrelated neuropeptide fragment.

The Takeaway

"GLP-5" isn't a hormone, an incretin, or a research frontier in metabolic medicine. It's a naming coincidence between a pyroglutamate-modified Substance P fragment and the acronym that made GLP-1 a household term. The real next chapter after GLP-1 is being written by multi-receptor agonists working through GIP, glucagon, and amylin pathways, not by a same-sounding entry in a peptide catalog.

This article is intended for scientific and educational purposes only. Peptides discussed on this site are strictly for laboratory and research use (RUO) and are not intended for human or animal consumption, diagnostic use, or therapeutic application. Helix does not provide dosing protocols or medical guidance.

For more on how Helix tests and verifies its products, see our Science page.

Sources

• Khan, S. et al. "Substance P-(1-7) and substance P-(5-11) locally modulate dopamine release in rat striatum." Eur. J. Pharmacol. 1995, 282(1-3), 229-233.

• Product and structural data, [Glp5] Substance P (5-11), CAS 56104-22-4 (MedChemExpress, TargetMol technical listings).

• Patel, S. & Niazi, S.K. "Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base." Pharmaceutics 2025, 17(8), 1036.

• "Triple Agonism Based Therapies for Obesity." PMC review, retatrutide Phase 2/3 data.